Table 5 Steady-state cerebrospinal fluid amyloid-β 1–40 reduction from baseline at 3 to 6 hours postdose, based on population pharmacokinetic/pharmacodynamic modeling from Study ALZ1005
JNJ-54861911 dose (mg) | Steady-state CSF Aβ1–40 percent reductions from baseline | ||
|---|---|---|---|
5th percentile | Median | 95th percentile | |
5 | 27% | 52% | 72% |
10 | 45% | 67% | 81% |
20 | 63% | 80% | 90% |
25 | 69% | 84% | 92% |
30 | 72% | 85% | 93% |
50 | 80% | 91% | 96% |